625 related articles for article (PubMed ID: 28203307)
1. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M
Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307
[TBL] [Abstract][Full Text] [Related]
2. Concise review: Defining and targeting myeloma stem cell-like cells.
Abe M; Harada T; Matsumoto T
Stem Cells; 2014 May; 32(5):1067-73. PubMed ID: 24449391
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
Yang WC; Lin SF
Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
[TBL] [Abstract][Full Text] [Related]
4. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
Franqui-Machin R; Wendlandt EB; Janz S; Zhan F; Tricot G
Oncotarget; 2015 Dec; 6(38):40496-506. PubMed ID: 26415231
[TBL] [Abstract][Full Text] [Related]
6. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
7. Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.
Stefka AT; Park JH; Matsuo Y; Chung S; Nakamura Y; Jakubowiak AJ; Rosebeck S
Blood Cancer J; 2016 Aug; 6(8):e460. PubMed ID: 27540718
[No Abstract] [Full Text] [Related]
8. The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance.
Chen K; Zhang C; Ling S; Wei R; Wang J; Xu X
Cell Death Dis; 2021 Sep; 12(9):835. PubMed ID: 34482364
[TBL] [Abstract][Full Text] [Related]
9. Addressing intra-tumoral heterogeneity and therapy resistance.
Rybinski B; Yun K
Oncotarget; 2016 Nov; 7(44):72322-72342. PubMed ID: 27608848
[TBL] [Abstract][Full Text] [Related]
10. Getting to the root of the problem: the causes of relapse in multiple myeloma.
Chan Chung KC; Tiedemann RE
Expert Rev Anticancer Ther; 2014 Mar; 14(3):251-4. PubMed ID: 24397833
[TBL] [Abstract][Full Text] [Related]
11. Cancer Stem Cells: Basic Concepts and Therapeutic Implications.
Nassar D; Blanpain C
Annu Rev Pathol; 2016 May; 11():47-76. PubMed ID: 27193450
[TBL] [Abstract][Full Text] [Related]
12. New approaches to targeting the bone marrow microenvironment in multiple myeloma.
Gooding S; Edwards CM
Curr Opin Pharmacol; 2016 Jun; 28():43-9. PubMed ID: 27018230
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma.
Kumar D; Gorain M; Kundu G; Kundu GC
Mol Cancer; 2017 Jan; 16(1):7. PubMed ID: 28137308
[TBL] [Abstract][Full Text] [Related]
14. Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.
Rastgoo N; Abdi J; Hou J; Chang H
J Hematol Oncol; 2017 Jun; 10(1):121. PubMed ID: 28623912
[TBL] [Abstract][Full Text] [Related]
15. Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells.
Bourguignon LYW; Earle C; Shiina M
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837080
[TBL] [Abstract][Full Text] [Related]
16. Targeting Multiple Myeloma Cancer Stem Cells with Natural Products - Lessons from Other Hematological Malignancies.
Issa ME; Cretton S; Cuendet M
Planta Med; 2017 Jun; 83(9):752-760. PubMed ID: 28472843
[TBL] [Abstract][Full Text] [Related]
17. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting.
Eun K; Ham SW; Kim H
BMB Rep; 2017 Mar; 50(3):117-125. PubMed ID: 27998397
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells in multiple myeloma.
Ghosh N; Matsui W
Cancer Lett; 2009 May; 277(1):1-7. PubMed ID: 18809245
[TBL] [Abstract][Full Text] [Related]
19. The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma.
Gunn EJ; Williams JT; Huynh DT; Iannotti MJ; Han C; Barrios FJ; Kendall S; Glackin CA; Colby DA; Kirshner J
Leuk Lymphoma; 2011 Jun; 52(6):1085-97. PubMed ID: 21417826
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
Furukawa Y; Kikuchi J
Int J Hematol; 2016 Sep; 104(3):281-92. PubMed ID: 27411688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
